International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 333-337 , April 2010

Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli

  • Sho Takahata

      Affiliations

    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 45 545 3139; fax: +81 45 541 1768.
    • ,
  • Takashi Ida

      Affiliations

    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan
    • ,
  • Toru Hiraishi

      Affiliations

    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan
    • ,
  • Shiro Sakakibara

      Affiliations

    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan
    • ,
  • Kazunori Maebashi

      Affiliations

    • Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan
    • ,
  • Shinichi Terada

      Affiliations

    • Product Management & Promotion Department, Pharmaceutical Marketing Division, Meiji Seika Kaisha, Ltd., 2-4-16 Kyobashi, Chuo-ku, Tokyo, Japan
    • ,
  • Tetsuro Muratani

      Affiliations

    • Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
    • Present address: Department of Clinical Laboratory, Kyurin Corporation, Kitakyushu, Japan.
    • ,
  • Tetsuro Matsumoto

      Affiliations

    • Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
    • ,
  • Chikara Nakahama

      Affiliations

    • Nakahama Clinic, Osaka, Japan
    • ,
  • Kazunori Tomono

      Affiliations

    • Division of Infection Control and Prevention, Osaka University Hospital, Osaka, Japan

Received 5 August 2009 ,Accepted 19 November 2009.

References 

  1. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736–738
  2. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54:1164–1178
  3. Muratani T, Matsumoto T. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int J Antimicrob Agents. 2006;28(Suppl. 1):S10–S13
  4. Stelling JM, Travers K, Jones RN, Turner PJ, O’Brien TF, Levy SB. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis. 2005;11:873–882
  5. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745–758
  6. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, et al. EAU guidelines for the management of urinary and male genital tract infections. Eur Urol. 2001;40:576–588
  7. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364–386
  8. Kadner RJ, Winkler HH. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol. 1973;113:895–900
  9. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003;47:2850–2858
  10. Horii T, Kimura T, Sato K, Shibayama K, Ohta M. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother. 1999;43:789–793
  11. Arca P, Rico M, Braña AF, Villar CJ, Hardisson C, Suárez JE. Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother. 1988;32:1552–1556
  12. Cordaro JC, Melton T, Stratis JP, Atagün M, Gladding C, Hartman PE, et al. Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol. 1976;128:785–793
  13. Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M. Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem. 2003;67:2030–2033
  14. Shimizu M, Nonomiya T, Shigenobu F, O’Hara K, Sawai T. Fosfomycin resistance in Escherichia coli in Japan. J Antibiot (Tokyo). 1998;51:889–892
  15. Yoshida I, Fujimura T, Jinushi Y, Higashiyama I, Sugimori G, Yamano Y. Antimicrobial susceptibility of clinical isolates of aerobic Gram-negative bacteria in 2002. Jpn J Chemother. 2006;54:355–377[in Japanese]
  16. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003;51:69–76
  17. Ishigami J, Ohbe S, Mita T, Miyazaki S, Akita Y, Okunishi H. Clinical evaluation of fosfomycin for acute lower urinary tract infection: a double blind study. Acta Urol Jpn. 1975;21:971–977[in Japanese]
  18. Fujita K, Narita K, Munakata A, Murayama T. A clinical experience of fosfomycin tablet on cystitis. Jpn J Antibiot. 1988;41:567–570[in Japanese]
  19. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents. 1998;10:39–47
  20. Bonfiglio G, Mattina R, Lanzafame A, Cammarata E, Tempera G. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy. 2005;51:162–166
  21. Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother. 1994;34:853–858
  22. Blattner FR, Plunkett G, Bloch CA, Perna NT, Burland V, Riley M, et al. The complete genome sequence of Escherichia coli K-12. Science. 1997;277:1453–1462
  23. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
  24. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure. 1996;4:1465–1474
  25. Yoon HJ, Lee SJ, Mikami B, Park HJ, Yoo J, Suh SW. Crystal structure of UDP-N-acetylglucosamine enolpyruvyl transferase from Haemophilus influenzae in complex with UDP-N-acetylglucosamine and fosfomycin. Proteins. 2008;71:1032–1037
  26. Kim DH, Lees WJ, Kempsell KE, Lane WS, Duncan K, Walsh CT. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry. 1996;35:4923–4928
  27. McCoy AJ, Sandlin RC, Maurelli AT. In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance. J Bacteriol. 2003;185:1218–1228
  28. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science. 2003;301:616–620
  29. Island MD, Wei BY, Kadner RJ. Structure and function of the uhp genes for the sugar phosphate transport system in Escherichia coli and Salmonella typhimurium. J Bacteriol. 1992;174:2754–2762
  30. Tsuruoka T, Yamada Y. Characterization of spontaneous fosfomycin (phosphonomycin)-resistant cells of Escherichia coli B in vitro. J Antibiot (Tokyo). 1975;28:906–911
  31. Kasai T, Tsuruoka T. Pathogenicity of fosfomycin-resistant strains isolated from Escherichia coli. Jpn J Antibiot. 1999;52:34–40[in Japanese]
  32. Galatti L, Sessa A, Mazzaglia G, Pecchioli S, Rossi A, Cricelli C, et al. Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 year descriptive study. J Antimicrob Chemother. 2006;57:551–556
  33. Gobernado M, Valdés L, Alós JI, García-Rey C, Dal-Ré R, García-de-Lomas J, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter. 2007;20:68–76
  34. Brown ED, Vivas EI, Walsh CT, Kolter R. MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli. J Bacteriol. 1995;177:4194–4197
  35. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents. 2003;22(Suppl. 2):S53–S59

PII: S0924-8579(09)00545-7

doi: 10.1016/j.ijantimicag.2009.11.011

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 333-337 , April 2010

Article Tools